Rani raises cash for 'holy grail' of oral formulations for biologics
This article was originally published in Scrip
Executive Summary
Rani Therapeutics completed a Series B funding round to finance technology that's designed to convert biologics into pills, which could give pharmaceutical companies a competitive advantage and extend the patent lives of blockbuster injectable drugs, according to the company's chairman and CEO Mir Imran.
You may also be interested in...
Finance Watch: VC Mega-Rounds Fund Wide Array, From Respiratory To Rare Diseases
Private Company Edition: China-focused Nuance Pharma led recent venture capital deals with a $181m series D round, RayzeBio closed a $105m series B and SciNeuro launched with $100m plus other notable rounds from Edgewise, Reneo, BioAge and others.
Shire Explores Robotic Pill Potential For Hemophilia
The company has linked up with Rani Therapeutics to develop a simple-to-swallow capsule that is able to provide an alternative to current injectable therapies for hemophilia A.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.